FrancophonIA/ELRC3.0 huggingface dataset:
English: Each tablet contains 200 mg of eslicarbazepine acetate.
Estonian: Üks tablett sisaldab 200 mg eslikarbasepiinatsetaati.
English: Zebinix is not recommended in patients with severe renal disease.
Estonian: Raskete maksahäiretega patsientidel ei ole soovitatav Zebinixi kasutada.
English: • Slower or irregular heart beat;
Estonian: • südametegevuse aeglustumine või südame rütmihäired
English: Valproate and levetiracetam
Estonian: • luu ainevahetushäired
English: Povidone K 29/32
Estonian: FARMATSEUTILISED ANDMED 6.1 Abiainete loetelu povidoon K 29/32 kroskarmelloosnaatrium magneesiumstearaat
English: Store the bottle and the oral syringe together in the carton until next use.
Estonian: Pange pudel ja süstal järgmise korrani tagasi karpi.
English: Zebinix 200 mg tablets are white and oblong.
Estonian: Zebinix 200 mg tabletid on valged ja piklikud.
English: Based on individual response, the dose of eslicarbazepine acetate may need to be increased if used concomitantly with carbamazepine.
Estonian: Võimalik, et kasutamisel koos karbamasepiiniga on individuaalsest ravivastusest lähtuvalt vaja suurendada eslikarbasepiinatsetaadi annust.
English: Shake well before use.
Estonian: Enne kasutamist loksutage põhjalikult, kuid ettevaatlikult.
English: HPDE bottles carton and HPDE bottles of 60 tablets
Estonian: Pappkarbis lastekindla polüpropüleenkorgiga HDPE-pudelid, milles on 60 tabletti.
English: Zebinix 400 mg tablets
Estonian: Zebinix 400 mg tabletid
English: Zebinix 600 mg tablets
Estonian: Zebinix 600 mg tabletid
English: Ossification delays, reduced foetal weights, an increase in minor skeletal and visceral anomalies were observed at maternal toxic doses in embryotoxicity studies in mice, rats and rabbits.
Estonian: Embrüotoksilisuse uuringutes täheldati hiirtel, rottidel ja küülikutel emasloomale toksilistel annustel hilinenud luustumist, lootekaalu vähenemist ning kergete luustiku ja siseelundite patoloogiate esinemissageduse tõusu.
English: • Diarrhoea;
Estonian: • kõhulahtisus
English: Eslicarbazepine acetate was tested at doses of 1,200 mg and 1,600 mg once-daily.
Estonian: Eslikarbasepiinatsetaati katsetati üks kord ööpäevas manustatavates 1200 mg ja 1600 mg annustes.
English: Myalgia, bone metabolism disorder, muscular weakness, pain in extremity
Estonian: Lihaste, luustiku ja sidekoe kahjustused müalgia, luu ainevahetuse häired, lihasnõrkus, valu jäsemetes
English: Zebinix 600 mg tablets are white and oblong.
Estonian: Zebinix 600 mg tabletid on valged ja piklikud.
English: Paediatric population
Estonian: • epilepsiahood
English: HDPE bottles with polypropylene child resistant closure, placed into cardboard boxes, containing 90 tablets.
Estonian: Pappkarbis lastekindla polüpropüleenkorgiga HDPE-pudelid, milles on 90 tabletti.
English: Respiratory, thoracic and mediastinal disorders
Estonian: Respiratoorsed, rindkere ja mediastiinumi häired epistaksis, valu rindkeres
English: Package leaflet: Information for the user Zebinix 200 mg tablets
Estonian: Pakendi infoleht: teave kasutajale Zebinix 200 mg tabletid
English: The tablets have ‘ESL 200'engraved on one side and are scored on the other side, with a length of 11 mm.
Estonian: Tablettide ühele küljele on pressitud ‘ESL 200' ja teisel küljel on poolitusjoon, tableti pikkus on 11 mm. Tableti saab jagada võrdseteks annusteks.
English: There have been reports of decreased bone mineral density, osteopenia, osteoporosis and fractures in patients on long-term therapy with the structurally related antiepileptic drugs carbamazepine and oxcarbazepine.
Estonian: Patsientidel, kes on saanud pikaajalist ravi sarnase struktuuriga antiepileptikumidega (karbamasepiin ja okskarbasepiin), on teatatud luu mineraaltiheduse languse, osteopeenia, osteoporoosi ja luumurdude juhtudest.
English: The score line is only there to help you break the tablet if you have difficulty swallowing it whole.
Estonian: Poolitusjoon on ainult poolitamise kergendamiseks, et hõlbustada ravimi allaneelamist.
English: Package leaflet: Information for the user Zebinix 800 mg tablets
Estonian: Pakendi infoleht: teave kasutajale Zebinix 800 mg tabletid
English: Zebinix 800 mg tablets Eslicarbazepine acetate
Estonian: Zebinix 800 mg tabletid Eslikarbasepiinatsetaat
English: Zebinix 400 mg tablets Eslicarbazepine acetate
Estonian: Zebinix 400 mg tabletid Eslikarbasepiinatsetaat
English: Zebinix 200 mg tablets Eslicarbazepine acetate
Estonian: Zebinix 200 mg tabletid Eslikarbasepiinatsetaat
English: Zebinix 600 mg tablets Eslicarbazepine acetate
Estonian: Zebinix 600 mg tabletid Eslikarbasepiinatsetaat
English: • Muscle pain, pain in limbs, muscular weakness;
Estonian: • lihasvalu, valu jäsemetes, lihasnõrkus
English: Package leaflet: Information for the user Zebinix 400 mg tablets
Estonian: Pakendi infoleht: teave kasutajale Zebinix 400 mg tabletid
English: Headache, disturbance in attention, tremor, ataxia, balance disorder
Estonian: Südame häired südamepekslemine, bradükardia
English: Pancreatitis
Estonian: Okskarbasepiin
English: 2 What you need to know before you take Zebinix Do not take Zebinix:
Estonian: Mis ravim on Zebinix ja milleks seda kasutatakse Mida on vaja teada enne Zebinixi võtmist Kuidas Zebinixi võtta
English: Package leaflet: Information for the user Zebinix 600 mg tablets
Estonian: Pakendi infoleht: teave kasutajale Zebinix 600 mg tabletid
English: • Migraine;
Estonian: • valu rindkeres
English: White circular biconvex tablets, engraved ‘ESL 400'on one side and scored on the other side, with a diameter of 11 mm..
Estonian: Valged 11 mm läbimõõduga ümmargused kaksikkumerad tabletid, mille ühel küljel on graveering ‘ESL 400' ja teisel küljel on poolitusjoon.
English: The doses of the active comparator, carbamazepine controlled release, were 200 mg, 400 mg and 600 mg, twice-daily.
Estonian: Aktiivset võrdlusravimit, karbamasepiini kontrollitult vabastavat ravimit, manustati kaks korda ööpäevas annustes 200 mg, 400 mg ja 600 mg. Kõik osalejad randomiseeriti madalaima annuse rühma ning suuremale annusele viidi üle ainult need osalejad, kellel tekkisid krambihood.
English: Toxic epidermal necrolysis, StevensJohnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), angioedema, urticaria
Estonian: Naha ja nahaaluskoe kahjustused nahalööve alopeetsia, nahakuivus, hüperhidroos, erüteem, nahakahjustus, sügelus, allergiline nahapõletik toksiline epidermaalne nekrolüüs, Stevensi-Johnsoni sündroom, ravimireaktsioon koos eosinofiilia ja süsteemsete sümptomitega (DRESSsündroom), angioödeem, urtikaaria
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
Estonian: VÄLISPAKENDIL JA SISEPAKENDIL PEAVAD OLEMA JÄRGMISED ANDMED Välispakend / pudel
English: Carbamazepine
Estonian: Topiramaat
English: • Seizures;
Estonian: • nahalööve
English: • Shaking;
Estonian: • migreen
English: White oblong tablets, engraved ‘ESL 600'on one side and scored on the other side, with a length of 17.3 mm.
Estonian: Valged piklikud tabletid, mille ühel küljel on graveering ‘ESL 600' ja teisel küljel on poolitusjoon.
English: Zebinix is not recommended if you have severe kidney problems.
Estonian: Kui teil on rasked neeruprobleemid, ei ole teil soovitatav Zebinixi kasutada.
English: • Clumsiness;
Estonian: • kõhukinnisus
English: • Bone metabolism disorder;
Estonian: • ebanormaalne puutetundlikkus
English: • Weight loss;
Estonian: • kehakaalu langus
English: Suspension of the marketing authorisations should be lifted when bioequivalence to an EU Reference Medicinal Product has been established based on a bioequivalence study conducted visà-vis the EU Reference Medicinal Product.
Estonian: müügilubade peatamine tuleks lõpetada, kui bioekvivalentsus ELi võrdlusravimiga on tõestatud ELi võrdlusravimi suhtes läbiviidud bioekvivalentsusuuringu põhjal.
English: The National Competent Authorities of Member States or Reference Member States if applicable, shall ensure that the following condition is fulfilled by the MAH(s):
Estonian: Liikmesriikide või asjakohasel juhul viiteliikmesriikide pädevad asutused peavad tagama, et müügiloa hoidja(d) täidab (täidavad) järgmise tingimuse:
English: Annex III Condition for lifting the suspension of the Marketing Authorisations
Estonian: III lisa Müügilubade peatamise lõpetamise tingimus
English: What measures are being taken to ensure the safe and effective use of Zinplava?
Estonian: Mis meetmed võetakse, et tagada Zinplava ohutu ja efektiivne kasutamine?
English: The full EPAR for Zinplava can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Zinplava kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The recommended dose is 10 mg per kilogram bodyweight.
Estonian: Soovitatav annus on 10 mg kehamassi kg kohta.
English: What is Zinplava and what is it used for?
Estonian: Mis on Zinplava ja milleks seda kasutatakse?
English: Other information about Zinplava
Estonian: Muu teave Zinplava kohta
English: Zinplava bezlotoxumab
Estonian: Zinplava bezlotoksumaab
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) therefore decided that Zinplava's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Zinplava kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: The most common side effects with Zinplava (seen in more than 4 in 100 patients) are nausea (feeling sick), diarrhoea, fever and headache.
Estonian: Zinplava kõige sagedamad kõrvalnähud (esinenud enam kui 4 patsiendil 100st) on iiveldus, kõhulahtisus, palavik ja peavalu.
English: It is given as a single infusion lasting around 1 hour.
Estonian: Zinplavat manustatakse ligikaudu 1 tund kestva ühekordse infusioonina.
English: It is not intended to provide practical advice on how to use Zinplava.
Estonian: Hindamisaruandes ei anta Zinplava kasutamise praktilisi nõuandeid.
English: Why is Zinplava approved?
Estonian: Miks Zinplava heaks kiideti?
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Zinplava have been included in the summary of product characteristics and the package leaflet.
Estonian: Zinplava ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Similar effects have been seen in patients on placebo.
Estonian: Sarnaseid nähtusid täheldati platseebot saanud patsientidel.
English: In the second study, figures were 16% (62 out of 395) for Zinplava and 26% (97 out of 378) for placebo.
Estonian: Teises uuringus olid vastavad näitajad Zinplava rühmas 16% (62 patsienti 395st) ja platseeborühmas 26% (97 patsienti 378st).
English: The effect was mainly seen in patients at higher risk of C. difficile infection coming back (such as older patients or those with a weakened immune system).
Estonian: Toimet täheldati peamiselt patsientidel, kellel oli C. difficile infektsiooni kordumise suurem risk (nt eakad või nõrgenenud immuunsüsteemiga patsiendid).
English: This is a summary of the European public assessment report (EPAR) for Zinplava.
Estonian: See on ravimi Zinplava Euroopa avaliku hindamisaruande kokkuvõte.
English: What are the risks associated with Zinplava?
Estonian: Mis riskid Zinplavaga kaasnevad?
English: After an initial infection, some dormant forms of the bacteria (spores) may persist in the body and eventually produce further toxins, causing the symptoms to return.
Estonian: Pärast algset infektsiooni võivad bakterite mõned suikeseisundis vormid (eosed) organismis säilida ning hakata taas toksiine tekitama, nii et sümptomid taastuvad.
English: C. difficile bacteria produce toxins that damage the lining of the gut causing diarrhoea which may be severe.
Estonian: C. difficile bakterid tekitavad soole limaskesta kahjustavaid toksiine, mistõttu tekib kõhulahtisus, mis võib olla raske.
English: It is used to prevent future episodes of diarrhoea in patients who are taking antibiotics to treat their C. difficile infection and who are at high risk of the infection coming back.
Estonian: Seda kasutatakse kõhulahtisuse kordusepisoodide ennetamiseks patsientidel, kes võtavad C. difficile infektsiooni vastu antibiootikume ning kellel on infektsiooni kordumise suur risk.
English: antibody (a type of protein) that has been designed to attach to these toxins, blocking their action, thereby preventing further damage and diarrhoea from occurring.
Estonian: monoklonaalne antikeha (teatud valk), mis kinnitub nimetatud toksiinidele, blokeerib nende toime ja ennetab seeläbi edasist kahjustumist ja kõhulahtisuse kordumist.
English: For practical information about using Zinplava, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Zinplava kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: A new episode of diarrhoea was defined as 3 or more loose stools in 24 or fewer hours.
Estonian: Kõhulahtisuse kordusepisoodiks peeti vähemalt 3 vedela, vormitu väljaheite esinemist kuni 24 tunni jooksul.
English: For the full list of all side effects and restrictions with Zinplava, see the package leaflet.
Estonian: Zinplava kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Zinplava has been shown to be effective at preventing recurrence of C. difficile infection, particularly in patients at high risk of the infection coming back (which occurs in about 15 to 35% of cases and is particularly difficult to treat).
Estonian: Tõendati, et Zinplava ennetab C. difficile infektsiooni kordumist (esineb ligikaudu 15-35%-l juhtudest ja ravi on iseäranis keeruline) efektiivselt eelkõige suure riskiga patsientidel.
English: For more information about treatment with Zinplava, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Zinplavaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Zinplava is a medicine used in adults who have infections due to bacteria called Clostridium difficile that cause severe diarrhoea.
Estonian: Zinplava on ravim, mida kasutatakse rasket kõhulahtisust põhjustavate bakterite Clostridium difficile tekitatud infektsioonide raviks täiskasvanutel.
English: Zinplava is generally well tolerated with side effects similar to those observed in patients on placebo.
Estonian: Zinplava talutakse üldiselt hästi ning selle kõrvalnähud sarnanevad platseebot saanud patsientidel täheldatud kõrvalnähtudega.
English: In the first study, 17% of patients given Zinplava (67 out of 386) had a new episode of diarrhoea in the 12 weeks after treatment compared with 28% of patients given placebo (109 out of 395).
Estonian: Esimeses uuringus esines 12 ravijärgse nädala jooksul kõhulahtisuse kordusepisood Zinplava ravirühmas 17%-l (67 patsiendil 386st) ning platseeborühmas 28%-l (109 patsiendil 395st).
English: What benefits of Zinplava have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Zinplava kasulikkus?
English: How does Zinplava work?
Estonian: Kuidas Zinplava toimib?
English: Zinplava is available as a concentrate to be made into a solution for infusion (drip) into a vein.
Estonian: Zinplavat turustatakse infusioonilahuse (veeni tilgutatava lahuse) kontsentraadina.
English: Zinplava given during antibiotic treatment was shown to be more effective than placebo (a dummy treatment) at preventing a new episode of diarrhoea caused by C. difficile infection in 2 main studies involving a total of 2,655 patients.
Estonian: Kahes põhiuuringus, milles osales kokku 2655 patsienti, tõendati, et antibiootikumiravile lisatuna oli Zinplava C. difficile infektsioonist põhjustatud kõhulahtisuse kordusepisoodide ennetamisel efektiivsem kui platseebo (näiv ravim).
English: The medicine can only be obtained with a prescription.
Estonian: Zinplava on retseptiravim.
English: Bezlotoxumab is a monoclonal
Estonian: Bezlotoksumaab on
English: How is Zinplava used?
Estonian: Kuidas Zinplavat kasutatakse?
English: 21 October 2010
Estonian: 21. oktoober 2010
English: The full European Public Assessment Report for Intrinsa can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Intrinsa kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: What is Intrinsa?
Estonian: Mis on Intrinsa?
English: Intrinsa has been authorised since July 2006.
Estonian: Intrinsa sai müügiloa 2006. aasta juulis.
English: The company presented results of four studies in a total of 2,245 women with HSDD.
Estonian: Ettevõte esitas tulemused neljast uuringust, milles osales kokku 2245 HSDD-ga naist.
English: The CHMP noted that there was insufficient long-term data on the safety of the medicine in this larger group of patients and was therefore of the opinion that the medicine's benefits in these women did not outweigh its risks.
Estonian: Inimravimite komitee märkis, et pikaajalisi andmeid ravimi ohutuse kohta kõnealuses suuremas patsiendirühmas ei ole piisavalt, ja oli seepärast arvamusel, et ravimi kasulikkus nendel naistel ei ole suurem kui sellega kaasnevad riskid.
English: The letter from the company notifying the Agency of the withdrawal of the application is available under the tab ‘All documents'.
Estonian: Ettevõtte kiri, milles ta teatab ravimiametile oma taotluse tagasivõtmisest, on avaldatud jaotises „All documents“.
English: How far into the evaluation was the application when it was withdrawn?
Estonian: Millises järgus oli taotluse hindamine, kui see tagasi võeti?
English: The amount of testosterone in the blood is reduced after the menopause.
Estonian: Testosterooni hulk veres väheneb pärast menopausi.
English: On 22 September 2010, Warner Chilcott Pharmaceuticals UK Limited officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a change to the marketing authorisation for Intrinsa, to extend treatment to all postmenopausal women with hypoactive sexual desire disorder.
Estonian: 22. septembril 2010 teatas ettevõte Warner Chilcott Pharmaceuticals UK Limited ametlikult inimravimite komiteele oma soovist võtta tagasi ravimi Intrinsa müügiloa muutmistaotlus, et laiendada ravi kõikidele hüpoaktiivse seksuaalsoovi häirega menopausijärgses eas naistele.
English: This means that the CHMP had evaluated the documentation provided by the company and formulated two lists of questions.
Estonian: See tähendab, et inimravimite komitee oli ettevõtte esitatud dokumentidega tutvunud ja koostanud ettevõttele vastamiseks kaks küsimuste loetelu.
English: The active substance in Intrinsa, testosterone, is a natural sex hormone produced in men and, to a lesser extent, in women.
Estonian: Intrinsa toimeaine testosteroon on looduslik suguhormoon, mida tekib meeste ja vähemal määral naiste organismis.
English: The main measure of effectiveness was based on how frequently the women had ‘satisfying sexual episodes'.
Estonian: Efektiivsuse põhinäitajaks oli rahuldust pakkuva seksuaalse aktiivsuse episoodide esinemise sagedus naistel.
English: These women will also be receiving treatment with an oestrogen (a female sex hormone).
Estonian: Need naised kasutavad ka östrogeeni (naissuguhormoon).
English: The patch releases 300 micrograms of the active substance testosterone over 24 hours.
Estonian: Plaastrist vabaneb 300 µg toimeainet testosterooni ööpäevas.
English: They were given either Intrinsa or placebo (a dummy treatment).
Estonian: Osalejatele anti kas Intrinsat või platseebot (näiv ravim).
English: It is already used to treat women with hypoactive sexual desire disorder (HSDD, a lack of sexual thoughts and sexual desire) who have had their womb and both ovaries surgically removed.
Estonian: Ravim on juba kasutusel selliste hüpoaktiivse seksuaalsoovi häirega (HSDD - hypoactive sexual desire disorder, seksuaalsete mõtete ja seksuaalsoovi puudumine) naiste raviks, kelle emakas ja mõlemad munasarjad on kirurgiliselt eemaldatud.
English: The company informed the CHMP that there are no consequences for patients currently in clinical trials or compassionate use programmes with Intrinsa.
Estonian: Ettevõte teatas inimravimite komiteele, et taotluse tagasivõtmine ei mõjuta praegu Intrinsa kliinilistes uuringutes või eriloaga kasutamise programmides osalevaid patsiente.
English: Based on the review of the data and the company's response to the CHMP's lists of questions, at the time of the withdrawal, the CHMP had some concerns and was of the provisional opinion that Intrinsa could not have been approved for use in all postmenopausal women who have HSDD.
Estonian: Tuginedes esitatud andmete analüüsile ja ettevõtte vastustele inimravimite komitee esitatud küsimustele, nägi inimravimite komitee taotluse tagasivõtmise ajal põhjust ettevaatlikkuseks ja oli esialgsel seisukohal, et ravimi Intrinsa kasutamist kõikide HSDD-ga menopausijärgses eas naiste raviks ei ole võimalik heaks kiita.
English: Intrinsa is a transdermal patch (a patch that delivers a medicine across the skin).
Estonian: Intrinsa on transdermaalne plaaster (ravimi manustamiseks naha kaudu).
English: In postmenopausal women, Intrinsa was expected to release testosterone through the skin into the bloodstream to produce testosterone levels that match the levels seen before the menopause.
Estonian: Intrinsa pidi vabastama testosterooni menopausijärgses eas naistele vereringesse naha kaudu, suurendades testosteroonisisalduse menopausieelsele tasemele.
English: Intrinsa was expected to be used to treat HSDD in postmenopausal women with or without hormone treatment.
Estonian: Intrinsat kavatseti kasutada HSDD raviks hormoonravi saavatel ja mittesaavatel menopausijärgses eas naistel.
English: There are no consequences on the use of Intrinsa in the treatment of HSDD in women who have had their womb and both ovaries removed.
Estonian: Tagasivõtmine ei avalda mõju Intrinsa kasutamisele HSDD ravis naistel, kelle emakas ja mõlemad munasarjad on eemaldatud.
English: Intrinsa is expected to work in the same way as it does in women who have had their womb and both ovaries surgically removed.
Estonian: Intrinsa peaks toimima samamoodi kui see toimib naistel, kelle emakas ja mõlemad munasarjad on kirurgiliselt eemaldatud.
English: How is Intrinsa expected to work?
Estonian: Milline on Intrinsa eeldatav toime?
English: Some of the women had their womb and both ovaries surgically removed while others were postmenopausal women who had not had their womb or ovaries removed.
Estonian: Uuringutes osalesid nii naised, kelle emakas ja mõlemad munasarjad olid kirurgiliselt eemaldatud, kui ka menopausijärgses eas naised, kelle emakas ja munasarjad ei olnud eemaldatud.
English: What is happening with Intrinsa for its existing indication?
Estonian: Kuidas mõjutab tagasivõtmine Intrinsa kasutamist selle praeguse näidustuse raviks?
English: What was Intrinsa expected to be used for?
Estonian: Milleks kavatseti Intrinsat kasutada?
English: Low testosterone levels have been linked to low sexual desire and to reduced sexual thoughts and arousal.
Estonian: Seksuaalhuvi, soovi ja erutuse vähesust on seostatud testosterooni väikese
English: This was to incude all women who have been through the menopause and not only those who are ‘surgically postmenopausal' as result of having had their womb or ovaries removed.
Estonian: Näidustus pidi hõlmama kõiki menopausiga naisi: nii neid, kelle menopaus oli esile kutsutud emaka ja munasarjade eemaldamisega, kui ka menopausijärgses eas naisi.
English: The European Commission issued a decision on 12 March 2009.
Estonian: Euroopa Komisjon tegi otsuse 12. märtsil 2009.